choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Viiv Healthcare

Viiv Healthcare Newsletter
  • GSK’s oncology and HIV drugs drive 7% sales rise in 2025 04 Feb 2026 19:33 GMT

    … £554m in global sales. GSK’ HIV portfolio was also a key … ) continued to be GSK’s best-selling HIV drug in 2025, … 4 February, the CEO of GSK-owned ViiV Healthcare, Deborah Waterhouse, noted that … opportunity” to GSK’s future presence in the HIV market. Success …

  • Community HIV Projects Around Australia Awarded $200k In Grants 04 Feb 2026 10:56 GMT

    … People with HIV Australia, Positive Life NSW, Tasmanian Council on AIDS, Hepatitis … Health and WA AIDS Council. Sealing the gaps in HIV prevention and … living with HIV,” said Community Engagement and Partnerships Manager at ViiV Healthcare Australia …

  • Community innovations help ensure no one is left behind in Australia’s HIV response 03 Feb 2026 21:20 GMT

    … communities. Tasmanian Council on AIDS, Hepatitis and Related Diseases … Nations people living with HIV. WA AIDS Council Inc to … , CEO Tasmanian Council on AIDS, Hepatitis and Related Diseases, … from ViiV Healthcare is helping us launch a new HIV-specific …

  • HIV Therapeutics Market is expected to reach US$ 57.56 Billion by 2033 | DataM Intelligence 02 Feb 2026 11:09 GMT

    … potential. Market Opportunities The HIV Therapeutics Market offers substantial … . Boehringer Ingelheim International GmbH. Pfizer Inc. Theratechnologies Inc. Abbott … United States: January 2026: ViiV Healthcare launched a new long-acting …

  • Pfizer to Exit ViiV Healthcare as GSK and Shionogi Reshape Ownership 26 Jan 2026 00:01 GMT

    … exit their HIV-focused joint venture, ViiV Healthcare. The transaction values Pfizer’s exit … dividend as ViiV cancels Pfizer’s shares. GSK originally formed ViiV Healthcare with Pfizer in 2009 …

  • <![CDATA[Shionogi Acquires $2.1 Billion ViiV Healthcare Shareholdings from Pfizer ]]> 21 Jan 2026 02:09 GMT

    … deeper and broader interest in HIV and AIDS while also taking a … Shionogi. GSK, Pfizer and Shionogi Agree on Changes to ViiV Healthcare Shareholding ViiV Healthcare January 20 …

  • GSK and Shionogi agree to replace Pfizer's stake in ViiV Healthcare 21 Jan 2026 07:55 GMT

    … in ViiV Healthcare. Pfizer will receive $1.875 billion and GSK will … in GBP). ViiV Healthcare, the global specialist HIV company, is dedicated … infectious diseases, with HIV being one of our … ongoing HIV research continues to contribute to ViiV’s pipeline …

  • Shionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up 20 Jan 2026 19:16 GMT

    … virus (HIV) medicines developer in a $2.13bn deal. ViiV Healthcare, which … on 19 January. ViiV Healthcare was established by Pfizer and GSK in a bid … (maraviroc). ViiV Healthcare’s current product portfolio consists of 15 prescription HIV medicines …

  • Pfizer to exit ViiV Healthcare in $1.9 bn deal 20 Jan 2026 13:39 GMT

    … on Tuesday ‌that Pfizer ‌will exit their HIV specialist ViiV Healthcare in a deal … ​majority holding in the global HIV company. Pfizer in ​December had warned … . drugmaker's ‍shares. GSK established ⁠ViiV Healthcare with ⁠Pfizer in 2009, with Shionogi …

  • Japan's Shionogi pays $2.13B to boost stake in ViiV Healthcare 20 Jan 2026 08:44 GMT

    … with British drugmaker GSK, raising its stake in the HIV drugmaker to … Pfizer’s shares. GSK will retain its 78.3% majority stake in ViiV Healthcare … pipeline of long-acting injectable ⁠HIV treatments and prevention medicines. News …

Satisfied with the content?

Continue to create your account.